Research Topics
| Peter A McSweeneySummaryAffiliation: University of Colorado Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsP A McSweeney
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA
Blood 97:3390-400. 2001..Future protocol modifications should reduce rejection and GVHD, thereby facilitating studies of allogeneic immunotherapy for a variety of malignancies. (Blood. 2001;97:3390-3400)..
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney
University of Colorado Health Sciences Center, Denver 80262, USA
Blood 100:1602-10. 2002..Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies...- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosingMichael B Maris
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 12:454-65. 2006..Nonmyeloablative conditioning with postgrafting cyclosporine and MMF given 3 times daily allowed 95% durable engraftment of unrelated donor G-PBMC grafts... - High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 110:1388-96. 2007..Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial... - Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantationChristian Junghanss
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
Br J Haematol 123:662-70. 2003.... - Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplantLyle C Feinstein
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 9:266-72. 2003..4; P =.04). Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting... - Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantationFrederic Baron
Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
J Clin Oncol 24:4150-7. 2006..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches... - Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myelomaGeorge E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 13:423-32. 2007.... - Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseasesRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 9:583-91. 2003..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study... - Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningMohamed L Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 26:4912-20. 2008..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients... - Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosisRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Arthritis Rheum 54:1982-6. 2006..To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc)... - Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remissionLyle C Feinstein
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Br J Haematol 120:281-8. 2003..While follow-up is short, this analysis demonstrates that the procedure is sufficiently safe to be studied in a wider group of patients... - Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control studyChristian Junghanss
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 8:512-20. 2002..This risk is an important consideration for the future development of preventive strategies... - Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allograftingMarcello Rotta
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 113:3383-91. 2009..03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues... - Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesMohamed L Sorror
Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
JAMA 306:1874-83. 2011..A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions... - High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisRichard A Nash
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
Blood 102:2364-72. 2003..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy... - Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningChristoph Kahl
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 110:2744-8. 2007..The latter might benefit from cytoreductive treatment before HCT... - HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemiaFrederic Baron
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 11:272-9. 2005..Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression... - Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseasesGeorge E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
Int J Hematol 76:184-9. 2002..Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options... 
Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantationMohamed Sorror
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Cancer 112:1992-2001. 2008..Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS)...- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationRainer Storb
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop D1 100, PO Box 19024, Seattle, WA 98109 1024
J Clin Oncol 31:1530-8. 2013..Improved results could come from methods that control progression of malignancy early after HCT and effectively prevent GVHD... - Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapyH Joachim Deeg
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
Blood 108:1485-91. 2006..Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions... - Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectivesMarco Mielcarek
Fred Hutchinson Cancer Research Center, University of Washington, School of Medicine, Seattle, Washington 98109 1024, USA
J Clin Immunol 22:70-4. 2002..Enhancing graft-versus-tumor effects by virtue of postgrafting vaccination of recipients against tumor-specific antigens may help to use this transplant approach more effectively in the treatment of solid tumors... - Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
Clin Immunol 113:285-98. 2004..In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells... - Treatment options for newly diagnosed patients with chronic myeloid leukemiaLori J Maness
University of Colorado Health Sciences Center, 4200 East Ninth Avenue B 190, Denver, CO 80262, USA
Curr Hematol Rep 3:54-61. 2004..Sensitive and specific monitoring techniques developed for CML may help further refine treatment with regard to using these and other emerging therapies... - Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplantYago Nieto
Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, Colorado 80262, USA
Clin Cancer Res 10:5076-86. 2004.... - Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancerYago Nieto
University of Colorado Bone Marrow Transplant Program and Department of Pathology, University of Colorado, Denver, CO 80262, USA
J Clin Oncol 20:707-18. 2002..To study prognostic factors after high-dose chemotherapy (HDC) for patients with stage IV oligometastatic breast cancer... - Reduced-intensity allogeneic transplantation for lymphomaKaren E Kogel
University of Colorado Health Sciences Center, Denver 80262, USA
Curr Opin Oncol 14:475-83. 2002..Controlled trials involving patients with earlier-stage disease appear warranted to define better the role of reduced-intensity allogeneic transplants in treating lymphomas... - Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancerYago Nieto
Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
Clin Cancer Res 10:7136-43. 2004.... - Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control studyChristian Junghanss
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109-1024, USA
Blood 99:1978-85. 2002..Therefore, nonmyeloablative HSCT patients should receive CMV surveillance beyond day 100 and pre-emptive ganciclovir treatment similar to that of myeloablative HSCT patients...